Операция илеотранспозиции как метод лечения сахарного диабета 2 типа

Распространенность и недостаточная эффективность лекарственной терапии сахарного диабета 2 типа (СД2) остается важной мировой проблемой. На фоне лечения компенсация СД2 достигается лишь у 30% больных, а ремиссия ? у минимальной доли пациентов. Клинически значимой альтернативой в лечении СД2 является бариатрическая хирургия, применяемая у пациентов с ожирением (ИМТ>35 кг/м²) и обеспечивающая достижение компенсации диабета в 76,8% случаев. Большой клинический интерес представляет возможность хирургического лечения СД2 у пациентов с ИМТ менее 35 кг/м². В последнее время появились результаты первых клинических исследований, посвященных противодиабетической эффективности операции илеотранспозиции (ИТ), которая направлена на нормализацию нарушенного инкретинового баланса за  счет проксимального перемещения участка подвздошной кишки. В данном обзоре подробно анализируются механизмы положительного эффекта ИТ при СД2, а также рассматриваются результаты немногочисленных клинических исследований в этой области.

сахарный диабет, инкретины, илеотранспозиция, бариатрическая хирургия

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes research and clinical practice. 2010;87(1):4–14. doi: 10.1016/j.diabres.2009.10.007

2. Сунцов Ю.И., Болотская Л.Л., Маслова О.В., и др. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации. // Сахарный диабет. – 2011. – №1 – С. 15–18. [Suntsov YI, Bolotskaya LL, Maslova OV, et al. Epidemiology of diabetes mellitus and prognosis of its prevalence in the Russian Federation. Diabetes mellitus. 2011;14(1):15–19.] doi: 10.14341/2072-0351-6245

3. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310(6972):83–88. doi: 10.1136/bmj.310.6972.83

4. Pories WJ, Mehaffey JH, Staton KM. The surgical treatment of type two diabetes mellitus. The Surgical clinics of North America. 2011;91(4):821–836, VIII. doi: 10.1016/j.suc.2011.04.008

5. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. The New England journal of medicine. 2012;366(17):1567–1576. doi: 10.1056/NEJMoa1200225

6. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–1737. doi: 10.1001/jama.292.14.1724

7. Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabetic Medicine. 2011;28(6):628–642. doi: 10.1111/j.1464-5491.2011.03306.x

8. Fried M, Ribaric G, Buchwald JN, et al. Metabolic Surgery for the Treatment of Type 2 Diabetes in Patients with BMI<35 kg/m2: An Integrative Review of Early Studies. Obesity surgery. 2010;20(6):776–790. doi: 10.1007/s11695-010-0113-3

9. Shimizu H, Timratana P, Schauer PR, Rogula T. Review of Metabolic Surgery for Type 2 Diabetes in Patients with a BMI < 35 kg/m(2). Journal of Obesity. 2012;2012:147256. doi: 10.1155/2012/147256

10. Garciacaballero M, Navarrete S, Favretti F, et al. Diabetes surgery in type 2 BMI 24–29 vs IMC 30–34 diabetic patients: is there differences among restrictive, malabsorptive and gastric bypass procedures? Nutricion hospitalaria. 2013;28 Suppl 2:23–30. doi: 10.3305/nh.2013.28.sup2.6710

11. Koopmans HS, Sclafani A, Fichtner C, Aravich PF. The effects of ileal transposition on food intake and body weight loss in VMH-obese rats. The American journal of clinical nutrition. 1982;35(2):284–293.

12. Ferri GL, Koopmans HS, Ghatei MA, et al. Ileal enteroglucagon cells after ileal-duodenal transposition in the rat. Digestion. 1983;26(1):10–16. doi: 10.1159/000198863

13. Smithy WB, Cuadros CL, Johnson H, Kral JG. Effects of ileal interposition on body weight and intestinal morphology in dogs. International journal of obesity. 1986;10(6):453–460.

14. Kotler DP, Koopmans H. Preservation of intestinal structure and function despite weight loss produced by ileal transposition in rats. Physiology & behavior. 1984;32(3):423–427. doi: 10.1016/0031-9384(84)90257-9

15. Ohtani N, Sasaki I, Naito H, et al. Effect of ileojejunal transposition on gastrointestinal motility, gastric emptying, and small intestinal transit in dogs. Journal of gastrointestinal surgery. 1999;3(5):516–523. doi: 10.1016/S1091-255X(99)80106-1

16. Shibata C, Funayama Y, Fukushima K, et al. Effect of ileo-jejunal transposition on ileal longitudinal smooth muscle contractility in vitro in rats. Journal of gastrointestinal surgery. 2004;8(8):1083–1089. doi: 10.1016/j.gassur.2004.03.003

17. Kohli R, Kirby M, Setchell KD, et al. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. American journal of physiology Gastrointestinal and liver physiology. 2010;299(3):G652–660. doi: 10.1152/ajpgi.00221.2010

18. Naslund E, Backman L, Holst JJ, et al. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obesity surgery. 1998;8(3):253–260. doi: 10.1381/096089298765554449

19. Naslund E, Hellstrom PM, Kral JG. The gut and food intake: an update for surgeons. Journal of gastrointestinal surgery. 2001;5(5):556–567. doi: 10.1016/S1091-255X(01)80095-0

20. Van Citters GW, Lin HC. The ileal brake: a fifteen-year progress report. Current gastroenterology reports. 1999;1(5):404–409. doi: 10.1007/s11894-999-0022-6

21. Gaitonde S, Kohli R, Seeley R. The role of the gut hormone GLP-1 in the metabolic improvements caused by ileal transposition. The Journal of surgical research. 2012;178(1):33–39. doi: 10.1016/j.jss.2011.04.044

22. Patriti A, Facchiano E, Annetti C, et al. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obesity surgery. 2005;15(9):1258–1264. doi: 10.1381/096089205774512573

23. Strader AD, Vahl TP, Jandacek RJ, et al. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. American journal of physiology endocrinology and metabolism. 2005;288(2):E447–453. doi: 10.1152/ajpendo.00153.2004

24. Ramzy AR, Nausheen S, Chelikani PK. Ileal transposition surgery produces ileal length-dependent changes in food intake, body weight, gut hormones and glucose metabolism in rats. Int J Obes (Lond). 2014;38(3):379–387. doi: 10.1038/ijo.2013.201

25. Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(49):19333–19338. doi: 10.1073/pnas.0707054104

26. Flint A, Raben A, Ersboll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International journal of obesity and related metabolic disorders. 2001;25(6):781–792. doi: 10.1038/sj.ijo.0801627

27. D'Alessio DA, Prigeon RL, Ensinck JW. Enteral Enhancement of Glucose Disposition by Both Insulin-Dependent and Insulin-Independent Processes: A Physiological Role of Glucagon-Like Peptide I. Diabetes. 1995;44(12):1433–1437. doi: 10.2337/diab.44.12.1433

28. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270–2276. doi: 10.2337/diabetes.48.12.2270

29. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes. 1999;48(12):2358–2366. doi: 10.2337/diabetes.48.12.2358

30. Buteau J, El-Assaad W, Rhodes CJ, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004;47(5):806–815. doi: 10.1007/s00125-004-1379-6

31. Patriti A, Aisa MC, Annetti C, et al. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number. Surgery. 2007;142(1):74–85. doi: 10.1016/j.surg.2007.03.001

32. Culnan DM, Albaugh V, Sun M, et al. Ileal interposition improves glucose tolerance and insulin sensitivity in the obese Zucker rat. American journal of physiology Gastrointestinal and liver physiology. 2010;299(3):G751–760. doi: 10.1152/ajpgi.00525.2009

33. Sabench Pereferrer F, Hernandez Gonzalez M, Blanco Blasco S, et al. [The effects of ileal transposition, gastrojejunal bypass and vertical gastroplasty on the regulation of ingestion in an experimental obesity model associated with diabetes mellitus type 2]. Cirugia espanola. 2009;85(4):222–228. doi: 10.1016/j.ciresp.2008.10.008

34. Boza C, Gagner M, Devaud N, et al. Laparoscopic sleeve gastrectomy with ileal transposition (SGIT): A new surgical procedure as effective as gastric bypass for weight control in a porcine model. Surgical endoscopy. 2008;22(4):1029–1034. doi: 10.1007/s00464-007-9685-y

35. Mason EE. Ileal [correction of ilial] transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Obesity surgery. 1999;9(3):223–228. doi: 10.1381/096089299765553070

36. de Paula AL, Macedo AL, Prudente AS, et al. Laparoscopic sleeve gastrectomy with ileal interposition ("neuroendocrine brake")--pilot study of a new operation. Surgery for obesity and related diseases. 2006;2(4):464–467. doi: 10.1016/j.soard.2006.03.005

37. Kota SK, Ugale S, Gupta N, et al. Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus. Indian journal of endocrinology and metabolism. 2012;16(4):589–598. doi: 10.4103/2230-8210.98017

38. DePaula AL, Macedo ALV, Rassi N, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surgical endoscopy. 2008;22(3):706–716. doi: 10.1007/s00464-007-9472-9

39. Kumar KV, Ugale S, Gupta N, et al. Ileal interposition with sleeve gastrectomy for control of type 2 diabetes. Diabetes Technol Ther. 2009;11(12):785–789. doi: 10.1089/dia.2009.0070

40. DePaula A, Stival A, Halpern A, Vencio S. Surgical Treatment of Morbid Obesity: Mid-term Outcomes of the Laparoscopic Ileal Interposition Associated to a Sleeve Gastrectomy in 120 Patients. Obesity surgery. 2011;21(5):668–675. doi: 10.1007/s11695-010-0232-x

41. Tinoco A, El-Kadre L, Aquiar L, et al. Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition. World journal of surgery. 2011;35(10):2238–2244. doi: 10.1007/s00268-011-1188-2

42. DePaula A, Macedo ALV, Schraibman V, et al. Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20–34. Surgical endoscopy. 2009;23(8):1724–1732. doi: 10.1007/s00464-008-0168-6

43. De Paula AL, Stival AR, Macedo A, et al. Prospective randomized controlled trial comparing 2 versions of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21–34 kg/m(2). Surgery for obesity and related diseases. 2010;6(3):296–304. doi: 10.1016/j.soard.2009.10.005

44. Kota SK, Ugale S, Gupta N, Modi KD. Laparoscopic ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes. Diabetes & metabolic syndrome. 2012;6(3):125–131. doi: 10.1016/j.dsx.2012.09.014

45. Yang YH, Yan J, Wu YJ, et al. [Impact of sleeve gastrectomy with ileal interposition duodenojejunal bypass operation on lipid metabolism in non-obese type 2 diabetes mellitus patients]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2013;16(3):273–275.

46. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Annals of surgery. 2004;239(1):1–11. doi: 10.1097/01.sla.0000102989.54824.fc

47. DePaula AL, Stival A, Halpern A, Vencio S. Thirty-day morbidity and mortality of the laparoscopic ileal interposition associated with sleeve gastrectomy for the treatment of type 2 diabetic patients with BMI <35: an analysis of 454 consecutive patients. World journal of surgery. 2011;35(1):102–108. doi: 10.1007/s00268-010-0799-3

48. Reis CE, Alvarez-Leite JI, Bressan J, Alfenas RC. Role of bariatric-metabolic surgery in the treatment of obese type 2 diabetes with body mass index <35 kg/m2: a literature review. Diabetes Technol Ther. 2012;14(4):365–372. doi: 10.1089/dia.2011.0127

49. Inabnet WB. Comment on: prospective randomized controlled trial comparing 2 versions of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21–34 kg/m(2). Surgery for obesity and related diseases. 2010;6(3):304–305. doi: 10.1016/j.soard.2009.11.005

50. Gagner M. Surgical treatment of nonseverely obese patients with type 2 diabetes mellitus: sleeve gastrectomy with ileal transposition (SGIT) is the same as the neuroendocrine brake (NEB) procedure or ileal interposition associated with sleeve gastrectomy (II-SG), but ileal interposition with diverted sleeve gastrectomy (II-DSG) is the same as duodenal switch. Surgical endoscopy. 2011;25(2):655–656. doi: 10.1007/s00464-010-1221-9

51. Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery. Obesity surgery. 2014;24(1):42–55. doi: 10.1007/s11695-013-1079-8